Osteoarthritis Structure Claim May Need Phase IV Clinical Data

Osteoarthritis agents could be eligible for a "slowing of structural deterioration" claim based on x-ray data and a commitment to do Phase IV studies measuring clinical impact on pain and function, members of FDA's Arthritis Advisory Committee agreed Feb. 20.